title: Intracavitary administration of OK-432 with subcutaneous priming for malignant ascites in a case of advanced renal cell carcinoma.
abstract: The intracavitary injection of OK-432 (a streptococcal preparation) with subcutaneous priming has been shown to be an effective immunotherapy for patients with malignant effusion. We applied this treatment in a case of advanced renal cell carcinoma with massive ascites. The patient received 0.2 Klinishe Einheit (KE) OK-432 in the subcutaneous injection twice (day 1 and day 7) followed by 10KE OK-432 intra-abdominal administration (day 9). The treatment was performed safely without major side-effects except for transient pyrexia. A significant reduction of ascites was noted 1 month after the treatment without subsequent re-accumulation. Intracavitary injection of OK-432 with subcutaneous priming seems to be a simple, safe and effective treatment for ascites in advanced renal cell carcinoma.
authors.affiliation: Department of Urology and Reproductive Medicine, Graduate School Tokyo Medical and Dental University, Japan. kageyys.uro@tmd.ac.jp
authors.forename: Yukio
authors.initials: Y
authors.lastname: Kageyama
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Sakai
authors.forename: Gaku
authors.initials: G
authors.lastname: Arai
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Hyochi
authors.forename: Masahito
authors.initials: M
authors.lastname: Suzuki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Masuda
authors.forename: Satoru
authors.initials: S
authors.lastname: Kawakami
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Hayashi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Okuno
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kihara
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D007267:Injections; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D010844:Picibanil